pro: IT WASN'T A GUESS!
There is ALWAYS a reason in the background when stock market things don't make sense!
As I posted, we just didn't know what it was!
Sure does look like some what to depress the PPS so they could buy before the news hit!
Strickly illegal but it happens!
Of course, IMO.
Before you get your panties in a wad, would you like to know what the conditions are for the other $900 Million and The Royalties? Of course you would!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Maybe this will be a GREAT deal but,
The Devil Is In The Details!!!
And, AS USUAL, we don't know what the details are.
Does the PPS go to $3 or 4, OR, does it go much higher?
Of course, IMO.
Haven't gone anywhere, bozo.
Sitting back and watching.
Devil Is Always In The Details!
Let's see what happens to the PPS over the next couple of months.
Then, we'll see who's the bozo!
Did they Halt GERN when it fell like a rock last March? I don't remember.
Would they currently Halt GERN for a jump of only a buck?
Or is it the Nature of the News that's causing the Halt?
Are you saying that its halted in AH?
Regular trading session is over.
30% is only about $.70.
I hope that it's more, much more!
Please specifically note the words "exclusive worldwide license."
"Menlo Park, Calif., November 13, 2014 - Geron Corporation (GERN) announced today that the company has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. ("Janssen") to develop and commercialize, imetelstat, Geron`s telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses. Imetelstat is a modified oligonucleotide that is currently in early phase clinical development for myelofibrosis (MF) and may have activity in other hematologic myeloid malignancies such as myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Under the terms of the agreement, Geron will receive an initial payment of $35 million due after the applicable waiting periods under the Hart-Scott Rodino Act and is eligible to receive additional payments up to a potential total of $900 million for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities will be managed through a joint governance structure, with Janssen responsible for operational implementation of these activities. All sales will be booked by Janssen."